文献速递免疫规划传染病防控与疫情报告

Nuvaxovid NVX-CoV2373疫苗安全性概况:澳大利亚2022至2023年10万剂次真实世界数据证据

Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023.
PubMed 文献 · Euro Surveill · 2024-01-01

该研究回顾性分析澳大利亚维多利亚州和西澳大利亚州SAFEVAC系统2022年2月14日至2023年6月30日自发报告的Nuvaxovid不良事件,共102946剂次接种收到356份报告。报告率第1剂高于第2剂、基础免疫高于加强免疫、女性高于男性;临床确认的严重不良事件包括胸痛94例、心肌炎2例、心包炎20例,未报告吉兰-巴雷综合征、血栓伴血小板减少综合征或归因于接种的死亡。分析确认了Nuvaxovid的安全性概况。

要点

  • 102946剂次Nuvaxovid接种共收到356份不良事件报告。
  • 报告率第1剂高于第2剂(率比1.5,p=0.0008),基础免疫高于加强免疫(率比2.4,p<0.0001)。
  • 临床确认严重不良事件包括胸痛94例(报告率91.3/10万剂)、心肌炎2例(1.9)、心包炎20例(19.4)。

核心结论

  • SAFEVAC协作数据模型实现了跨辖区临床审核数据的汇总,增加了Nuvaxovid安全性证据并提高了罕见事件的识别与描述机会。
  • 该分析确认了Nuvaxovid的安全性概况。

研究设计与样本

  • 对SAFEVAC(维多利亚州和西澳大利亚州综合疫苗安全监测系统)自发报告的免疫接种后不良事件(AEFI)进行回顾性观察性分析。
  • 分析2022年2月14日至2023年6月30日的报告,按接种者人口学特征、报告反应和COVID-19疫苗剂次分析,并比较每10万剂次的报告率。
  • 共收到356份AEFI报告,对应102946剂次Nuvaxovid接种。

主要发现

  • 报告率第1剂高于第2剂(率比1.5,p=0.0008)。
  • 报告率基础免疫高于加强免疫(率比2.4,p<0.0001)。
  • 报告率女性高于男性(率比1.4,p=0.004)。
  • 临床确认的严重AEFI包括胸痛94例(报告率91.3/10万剂)、心肌炎2例(报告率1.9/10万剂)、心包炎20例(报告率19.4/10万剂)。
  • 未报告吉兰-巴雷综合征或血栓伴血小板减少综合征,也未报告归因于接种的死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IntroductionNuvaxovid became available in Australia from February 2022, a year after the first COVID-19 vaccines. This protein-based vaccine was an alternative for people who had had an adverse event to and/or were hesitant to receive an mRNA or adenovirus-based COVID-19 vaccine. Although safety from clinical trials was reassuring, small trial populations, low administration rates and limited post-licensure intelligence meant potential rare adverse events were underinformed.AimWe aimed to describe Nuvaxovid's safety profile in a real-world setting.MethodsWe conducted a retrospective observational analysis of adverse events following immunisation (AEFI) spontaneously reported to SAFEVAC, the integrated vaccine safety surveillance system in Victoria and Western Australia. Reports from 14 February 2022 to 30 June 2023 were analysed by vaccinee demographics, reported reactions and COVID-19 vaccine dose, and compared as reporting rates (RR) per 100,000 doses administered.ResultsWe received 356 AEFI reports, following 102,946 Nuvaxovid doses administered. Rates were higher after dose 1 than dose 2 (rate ratio: 1.5, p = 0.0008), primary series than booster (rate ratio: 2.4, p < 0.0001), and in females vs males (rate ratio: 1.4, p = 0.004). Clinically confirmed serious AEFI included 94 cases of chest pain (RR = 91.3), two myocarditis (RR = 1.9) and 20 pericarditis (RR = 19.4). Guillain-Barré syndrome or thrombosis with thrombocytopaenia syndromes were not reported, nor deaths attributable to vaccination.ConclusionSAFEVAC's collaborative data model enabled pooling of clinically reviewed data across jurisdictions, increasing the safety profile evidence for Nuvaxovid and improving the odds for identification and description of rare events. This analysis affirmed the safety profile of Nuvaxovid.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Clothier HJ, Parker C, Mallard JH, et al. Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023. Euro Surveill. 2024. PMID: 39668765. doi:10.2807/1560-7917.ES.2024.29.50.2400164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。